Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer ; volume:23 ; number:1 ; day:4 ; month:4 ; year:2023 ; pages:1-10 ; date:12.2023
BMC cancer ; 23, Heft 1 (4.4.2023), 1-10, 12.2023
- Urheber
-
Asowed, Mustafa
Elander, Nils O.
Pettersson, Linn
Ekholm, Maria
Papantoniou, Dimitrios
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-023-10780-y
- URN
-
urn:nbn:de:101:1-2023081909163737744744
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Asowed, Mustafa
- Elander, Nils O.
- Pettersson, Linn
- Ekholm, Maria
- Papantoniou, Dimitrios
- SpringerLink (Online service)
Ähnliche Objekte (12)
The changing landscape of hormonal therapy in castration-resistant prostate cancer
Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Targeting molecular resistance in castration-resistant prostate cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
Ailanthone: a new potential drug for castration-resistant prostate cancer
Chromogranin A: a useful biomarker in castration-resistant prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
The changing landscape of hormonal therapy in castration-resistant prostate cancer
Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Targeting molecular resistance in castration-resistant prostate cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
Ailanthone: a new potential drug for castration-resistant prostate cancer
Chromogranin A: a useful biomarker in castration-resistant prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
The changing landscape of hormonal therapy in castration-resistant prostate cancer
Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Targeting molecular resistance in castration-resistant prostate cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
Ailanthone: a new potential drug for castration-resistant prostate cancer
Chromogranin A: a useful biomarker in castration-resistant prostate cancer